NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
Bladder Cancer
Conditions: official terms
Urinary Bladder Neoplasms
Conditions: Keywords
Detection of Bladder Cancer using NMP22 Urine Test Kit
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: Use of Nuclear Matrix Protein 22 Urine sample kit to determine Bladder Cancer
Type: Device
Overall Status
It is hypothesized that the NMP22(Nuclear Matrix Protein) Bladder Check ® Test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cell carcinoma at high risk of recurrence.
Detailed Description
Patients who have been previously treated for bladder cancer and are at a high risk for recurrence are being monitored for recurrence every 3 months with urine cytology and cystoscopy as part of standard care.The NMP22 Bladder Cancer ® Test Kit has been designed to provide an alternative to regular urine cytology. A urine sample will be provided and divided with a portion being used to assess the NMP22 test kit and the remaining sample to be sent to the lab for regular urine cytology. Patient charts will be reviewed by a medical student to record age, clinical stage, pathologic stage, time to disease progression/recurrence, site of recurrence and survival data.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- · History of pTis, pT1, large (>2cm) pTa or multiple pTa bladder cancer tumours.

Written Informed Consent prior to any study-related procedures.

Exclusion Criteria:

- History of bladder cancer tumours other than those listed in inclusion
London Health Sciences Centre
London, Ontario, Canada
Status: Recruiting
Start Date
January 2006
Completion Date
January 2009
Lawson Health Research Institute
Lawson Health Research Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page